154928-88-8

Basic information

• Product Name: 3-methyl-5-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)isoxazole
• Synonyms: 3-methyl-5-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)isoxazole
• CAS NO: 154928-88-8
• Molecular Weight: 225.288
• Mol File: 154928-88-8.mol

Chemical Properties

• CAS DataBase Reference: 3-methyl-5-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-5-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)isoxazole(154928-88-8)
• EPA Substance Registry System: 3-methyl-5-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)isoxazole(154928-88-8)

Safety Data

• Hazardous Substances Data: 154928-88-8(Hazardous Substances Data)

Upstream product

• 17739-45-6 2-(2-bromoethoxy)tetrahydropyran 
• 300-87-8 3,5-dimethyl-1,2-oxazole 

Downstream Products

• 154928-96-8 3-Methyl-6,7-dihydro-5(4H)-benzisoxazolone 
• 154928-89-9 β-(3-Methyl-5-isoxazolyl)propionic acid 

Relevant articles and documents

Isoxazole-Derived Amino Acids are Bromodomain-Binding Acetyl-Lysine Mimics: Incorporation into Histone H4 Peptides and Histone H3

A range of isoxazole-containing amino acids was synthesized that displaced acetyl-lysine-containing peptides from the BAZ2A, BRD4(1), and BRD9 bromodomains. Three of these amino acids were incorporated into a histone H4-mimicking peptide and their affinity for BRD4(1) was assessed. Affinities of the isoxazole-containing peptides are comparable to those of a hyperacetylated histone H4-mimicking cognate peptide, and demonstrated a dependence on the position at which the unnatural residue was incorporated. An isoxazole-based alkylating agent was developed to selectively alkylate cysteine residues in situ. Selective monoalkylation of a histone H4-mimicking peptide, containing a lysine to cysteine residue substitution (K12C), resulted in acetyl-lysine mimic incorporation, with high affinity for the BRD4 bromodomain. The same technology was used to alkylate a K18C mutant of histone H3.

COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present invention relates to a compound having a benzo seven-membered ring structure, and a preparation method therefor, and use thereof. The compound has a structure as represented by formula (I). Provided is use of the compound having the structure and prepared with the preparation method of the present invention, enantiomers, diastereomers, racemates and mixtures thereof of the compound, as well as chemically acceptable salts, crystalline hydrates and solvent mixtures of the compound and the enantiomers, diastereomers, racemates and mixtures thereof of the compound in the preparation of drugs for treating BET Bromodomain BRD4 activity or expression level related diseases.